Amarin Down On Lower '19 View, Posts Preliminary '18 Results
Zacks Investment Research | Jan 06, 2019 10:06PM ET
Amarin Corporation plc (NASDAQ:AMRN) reported preliminary results for 2018 and issued guidance for 2019. Notably, the results exceeded the Zacks Consensus Estimates. However, the stock declined almost 7.2% during after-hours trading on Jan 4. This downturn can be attributed to Amarin’s 2019 outlook that lagged market expectations.
A glimpse of the company’s price trend reveals that Amarin has outperformed the industry in a year’s time. The stock has soared 208.4% against the industry’s decline of 18.9%.
2018 Preliminary Results
For 2018, the company’s preliminary results put expected total revenues in the range of $224-$228 million. In the fourth quarter, revenues are estimated to be in between $72 million and $76 million. Full-year and fourth-quarter revenues are at record level for Amarin. The estimated full-year sales represent growth of approximately 24-26% from the year-ago period. Notably, sales growth is driven by strong demand for the company’s sole drug, Vascepa. It is approved as an adjunct to diet in order to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
The aforementioned guided range for 2018 lies above the Zacks Consensus Estimate of $218.37 million.
Meanwhile, the company ended 2018 with approximately $249 million in cash. Amarin also ended the year with no outstanding debt except for remaining balance on its royalty-bearing instrument. The instrument is being repaid at a rate of 10% of Vascepa revenues and has aggregate outstanding balance of less than $90 million.
2019 Outlook
Amarin expects revenues to grow by 50% to approximately $350 million in 2019 compared to 2018 figure, mostly from Vascepa sales in the United States. Markedly, this does not include any increase in revenues from a probable Vascepa label expansion in the United States. The projected number missed the Zacks Consensus Estimate of $421.77 million for 2019.
In the first quarter of 2019, the company expects to file supplemental new drug application (sNDA) seeking expanded label for Vascepa to include cardiovascular data from a late-stage cardiovascular outcomes study, REDUCE-IT. Data from the study has demonstrated a significant reduction in cardiovascular risk in patients with LDL-C (bad cholesterol) controlled by statin therapy. Vascepa also led to a 26% reduction in cardiovascular death, heart attacks and stroke compared to placebo. The company may look for priority review for the sNDA.
Amarin expects research & development expenses to be approximately $40 million in 2019, with the same to be higher in the first half. The company expects total operating expenses to increase by $25 million to $50 million from 2018-levels.
Get The News You Want
Amarin Corporation PLC Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.